Sorry, you need to enable JavaScript to visit this website.

Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer

TitoloNuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer
Tipo di pubblicazioneArticolo su Rivista peer-reviewed
Anno di Pubblicazione2008
AutoriBria, E., Visca P., Novelli Flavia, Casini B., Diodoro M.G., Perrone-Donnorso R., Botti C., Sperduti I., Facciolo F., Milella M., Cecere F.L., Cognetti F., and Mottolese M.
RivistaEuropean Journal of Surgical Oncology
Volume34
Paginazione593-598
ISSN07487983
Parole chiaveadult, aged, article, Biological, cancer survival, Carcinoma, Cell Nucleus, cell nucleus membrane, cellular distribution, Confidence interval, cytoplasm, disease free interval, Female, human, human tissue, Humans, immunohistochemistry, immunoreactivity, Italy, Lung Neoplasms, lung non small cell cancer, lymph node metastasis, major clinical study, male, Microtubule-Associated Proteins, Middle Aged, Multivariate analysis, Neoplasm Proteins, Neoplasm Staging, Non-Small-Cell Lung, overall survival, polyclonal antibody, prediction, priority journal, prognosis, protein bcl 2, protein expression, protein localization, Retrospective Studies, retrospective study, scoring system, survivin, Tissue Distribution, tumor marker, Tumor Markers, tumor volume, univariate analysis
Abstract

{Aim: Survivin is a member of the inhibitors of apoptosis (IAP) gene family that acts through pathways different from those involving the bcl-2 family. Largely undetectable in normal adult tissues, survivin is deregulated in most human cancers including non-small-cell lung cancer (NSCLC) and may represent a tumor marker with prognostic and therapeutic implications. Aim of our study was to determine the prognostic role of survivin as an apoptosis-related biomarker in a series of resected NSCLC patients. Methods: A retrospective series of resected NSCLC patients were retrieved from the files of the Regina Elena National Cancer Institute. Survivin was detected by immunohistochemistry (IHC) using a polyclonal antibody. Survivin displayed two kinds of immunoreactivity: (i) a diffuse cytoplasmic staining and (ii) a distinct nuclear staining. A score-scale to distinguish positive (score 1-2) vs. negative (score 0) pattern was applied. Clinical and biological (nuclear and cytoplasmic survivin staining) covariables were screened for a prognostic relationship with overall survival (OS) and disease-free survival (DFS) into the univariate and multivariate analyses. Results: Data referring to 116 NSCLC patients who underwent surgery for stage I-IIIA NSCLC were collected. Multivariate analyses identified tumor size, nodal status and nuclear, but not cytoplasmic, expression of survivin as significant independent predictors of OS, with a hazard ratio of 2.40 (95% CI 1.44, 3.99

Note

cited By 19

URLhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-41949108454&doi=10.1016%2fj.ejso.2007.06.002&partnerID=40&md5=2d78ab6183add62515c76c24341dbd1e
DOI10.1016/j.ejso.2007.06.002
Citation KeyBria2008593